By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ProBioGen AG 

Goethestr. 54

Berlin    13086  Germany
Phone: 49-30-9-24-00-60 Fax: 49-30-924006-19



Company News
ProBioGen AG Inks Another Commercial Glymaxx License And Contract Manufacturing Service Agreement On Immuno-Oncology Antibody 10/1/2015 10:34:01 AM
Anti-Ebola MVA Vaccine Produced On ProBioGen AG’s Avian AGE1.CR Cell Line Platform In Clinical Trials 6/2/2015 11:30:55 AM
ProBioGen AG Hunts For Staff In €20 Million Investment 9/9/2014 10:02:05 AM
ProBioGen AG Signs GlymaxX ADCC Enhancement Technology License Deal 6/23/2014 1:59:59 PM
ProBioGen AG And Merus Sign Deal On GlymaxX® ADCC Enhancement Technology 3/4/2014 9:46:09 AM
ProBioGen AG Announces Expansion Of Commercial Licenses With Emergent BioSolutions (EBS) For AGE1.CR® Viral Vaccine Manufacturing Production Platform 12/17/2013 9:43:53 AM
ProBioGen AG Signs Next GlymaxX® ADCC Technology Deal With TOP 10 Pharma Company for Therapeutic Antibody Platform 2/20/2013 11:47:45 AM
ProBioGen AG Launches Unique Portfolio of Engineered High-Performance Cell Lines for Biopharmaceutical Manufacturing 11/12/2012 1:01:56 PM
ProBioGen AG Introduces Novel Productivity-Boosting Technology for Therapeutic Protein Production: "Pathway Modulator" 6/14/2012 9:21:39 AM
Ceva Takes Commercial License for ProBioGen AG's AGE1.CR® Cell Line for Viral Vaccine Production 3/15/2012 9:50:23 AM